Vor Biopharma's CEO On Genome Engineering Of Hematopoietic Stem Cells
Source: Cell & Gene
Vor Biopharma's CEO Dr. Robert Ang explains the company's lead engineered hematopoietic cell (eHSC) product candidate, genome engineering of HSCs, and the cell manufacturing process needed to leverage genome engineering technologies for the cells they're creating.
This website uses cookies to ensure you get the best experience on our website. Learn more